nach oben

Erschienen in:

01.04.2005 | Article

Reduced whole-body lipid oxidation is associated with insulin resistance, but not with intramyocellular lipid content in offspring of type 2 diabetic patients

verfasst von: G. Lattuada, F. Costantino, A. Caumo, P. Scifo, F. Ragogna, F. De Cobelli, A. Del Maschio, L. Luzi, G. Perseghin

Erschienen in: Diabetologia | Ausgabe 4/2005

Einloggen, um Zugang zu erhalten

Abstract

Aims/hypothesis

Intramyocellular lipid accumulation and insulin resistance are thought to be due to reduced lipid oxidation in a human model of high risk of developing type 2 diabetes.

Methods

We studied 32 offspring of type 2 diabetic parents and 32 control individuals by means of DXA, indirect calorimetry, insulin clamp and ¹H MRS of the calf muscles, and differences between and within study groups were analysed before and after segregation by quartiles of fasting lipid oxidation.

Results

In comparison with control subjects, the offspring showed impaired insulin sensitivity, which was associated with higher fasting intramyocellular lipid content (Spearman’s rho −0.35; p=0.04), but fasting lipid oxidation did not differ between groups (1.21±0.46 vs. 1.25±0.37 mg·kg⁻¹ lean body mass per min; p=0.70). Nevertheless, offspring in the lowest quartile of lipid oxidation had the most severe impairment of insulin sensitivity and a strong association was shown between lipid oxidation and insulin sensitivity within quartiles (Spearman’s rho 0.47; p=0.01); this was not observed within the control group (Spearman’s rho 0.13; p=0.47). Intramyocellular lipid content was not significantly different within quartiles of lipid oxidation in either of the groups.

Conclusions/interpretation

Insulin sensitivity improved across increasing quartiles of fasting lipid oxidation in the offspring group, but remained constant in the control group, supporting the hypothesis that impaired fat oxidation is a primary pathogenic factor of insulin resistance in people with a genetic background for type 2 diabetes. Despite their association with impaired insulin sensitivity, soleus and tibialis anterior intramyocellular lipid content remained constant across increasing quartiles of fasting lipid oxidation within both groups.

Krssak M, Falk Petersen K, Dresner A et al (1999) Intramyocellular lipid concentrations are correlated with insulin sensitivity in humans: a ¹H NMR spectroscopy study. Diabetologia 42:113–116CrossRefPubMed

Jacob S, Machann J, Rett K et al (1999) Association of increased intramyocellular lipid content with insulin resistance in lean nondiabetic offspring of type 2 diabetic subjects. Diabetes 48:1113–1119PubMed

Perseghin G, Scifo P, De Cobelli F et al (1999) Intramyocellular triglyceride content is a determinant of in vivo insulin resistance in humans: a ¹H–¹³C NMR spectroscopy assessment in offspring of type 2 diabetic parents. Diabetes 48:1600–1606PubMed

Coldberg SR, Simoneau JA, Thaete FL, Kelley DE (1995) Skeletal muscle utilization of free fatty acids in women with visceral obesity. J Clin Invest 95:1846–1853PubMed

Kelley DE, Goodpaster B, Wing RR, Simoneau JA (1999) Skeletal muscle fatty acid metabolism in association with insulin resistance, obesity and weight loss. Am J Physiol 277:E1130–E1141

Blaak EE, Wagenmakers AJM, Glatz JFC et al (2000) Plasma FFA utilization and fatty acid-binding protein content are diminished in type 2 diabetic muscle. Am J Physiol Endocrinol Metab 279:E146–E154

Blaak EE, Wolffenbuttel BH, Saris WH, Pelsers MM, Wagenmakers AJ (2001) Weight reduction and the impaired plasma-derived free fatty acid oxidation in type 2 diabetic subjects. J Clin Endocrinol Metab 86:1638–1644

Mensink M, Blaak EE, van Baak MA, Wagenmakers AJ, Saris WH (2001) Plasma free fatty acid uptake and oxidation are already diminished in subjects at high risk for developing type 2 diabetes. Diabetes 50:2548–2554

Luzi L, Perseghin G, Tambussi G et al (2003) Intramyocellular lipid accumulation and reduced whole body lipid oxidation in HIV infected patients with lipodystrophy. Am J Physiol Endocrinol Metab 284:E274–E280

10.

Perseghin G, Scifo P, Danna M et al (2002) Normal insulin sensitivity and IMCL content in overweight humans are associated with higher fasting lipid oxidation. Am J Physiol Endocrinol Metab 283:E556–E564PubMed

11.

Goodpaster BH, Katsiaras A, Kelley DE (2003) Enhanced fat oxidation through physical activity is associated with improvements in insulin sensitivity in obesity. Diabetes 52:2191–2197

12.

Gan SK, Kriketos AD, Ellis BA, Thompson CH, Kraegen EW, Chisholm DJ (2003) Changes in aerobic capacity and visceral fat but not myocyte lipid levels predict increased insulin action after exercise in overweight and obese men. Diabetes Care 26:1706–1713

13.

Baecke JAH, Burema J, Frijters JER (1982) A short questionnaire for the measurement of habitual physical activity in epidemiological studies. Am J Clin Nutr 36:936–942PubMed

14.

Perseghin G, Scifo P, Pagliato E et al (2001) Gender factors affect fatty acid-induced insulin resistance in nonobese humans: effects of oral steroidal contraception. J Clin Endocrinol Metab 86:3188–3196

15.

Perseghin G, Lattuada G, Danna M et al (2003) Insulin resistance, intramyocellular lipid content and plasma adiponectin concentrations in patients with type 1 diabetes. Am J Physiol Endocrinol Metab 285:E1174–E1181

16.

Steele R (1959) Influence of glucose loading and of injected insulin on hepatic glucose output. Ann NY Acad Sci 82:420–431

17.

Bergman RN, Finegood DT, Ader M (1985) Assessment of insulin sensitivity in vivo. Endocr Rev 6:45–86PubMed

18.

Tappy L, Owen OE, Boden G (1988) Effect of hyperinsulinemia on urea pool size and substrate oxidation rates. Diabetes 37:1212–1216

19.

Perseghin G, Comola M, Scifo P et al (2004) Postabsorptive and insulin-stimulated energy and protein metabolism in patients with myotonic dystrophy type 1. Am J Clin Nutr 80:357–364

20.

Warram JH, Martin BC, Krolewski AS, Soeldner JS, Kahn CR (1990) Slow glucose removal rate and hyperinsulinemia precede the development of type II diabetes in the offspring of diabetic parents. Ann Int Med 113:909–915

21.

Perseghin G, Ghosh S, Gerow K, Shulman GI (1997) Metabolic defects in lean, non-diabetic offspring of NIDDM parents: a cross-sectional study. Diabetes 46:1001–1009

22.

Petersen KF, Dufour S, Befroy D, Garcia R, Shulman GI (2004) Impaired mitochondrial activity in the insulin-resistant offspring of patients with type 2 diabetes. N Engl J Med 350:664–671CrossRefPubMed

23.

He J, Watkins S, Kelley DE (2001) Skeletal muscle lipid content and oxidative enzyme activity in relation to muscle fiber type in type 2 diabetes and obesity. Diabetes 50:817–823PubMed

24.

Gaster M, Rustan AC, Aas V, Beck-Nielsen H (2004) Reduced lipid oxidation in skeletal muscle from type 2 diabetic subjects may be of genetic origin. Evidence from cultured myotubes. Diabetes 53:542–548

25.

Kelley DE, He J, Menshikova EV, Ritov VB (2002) Dysfunction of mitochondria in human skeletal muscle in type 2 diabetes. Diabetes 51:2944–2950

26.

Petersen KF, Befroy D, Dufour S et al (2003) Mitochondrial dysfunction in the elderly: possible role in insulin resistance. Science 300:1140–1142CrossRef

27.

Schrauwen P, Hesselink MKC (2004) Oxidative capacity, lipotoxicity, and mitochondrial damage in type 2 diabetes. Diabetes 53:1412–1417PubMed

28.

Ek J, Andersen G, Urhammer SA et al (2001) Mutation analysis of peroxisome proliferator-activated receptor-gamma coactivator-1 (PGC-1) and relationships of identified amino acid polymorphisms to type II diabetes mellitus. Diabetologia 44:2220–2226CrossRefPubMed

29.

Muller YL, Bogardus C, Beamer BA, Shuldiner AR, Baier LJ (2003) A functional variant in the peroxisome proliferator-activated receptor gamma2 promoter is associated with predictors of obesity and type 2 diabetes in Pima Indians. Diabetes 52:1864–1871

30.

Mootha VK, Lindgren CM, Eriksson KF et al (2003) PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nat Genet 34:267–273

31.

Patti ME, Butte AJ, Crunkhorn S et al (2003) Coordinated reduction of genes of oxidative metabolism in humans with insulin resistance and diabetes: potential role of PGC1 and NRF1. Proc Nat Acad Sci U S A 100:8466–8471

32.

Thamer C, Machann J, Bachmann O et al (2003) Intramyocellular lipids: anthropometric determinants and relationships with maximal aerobic capacity and insulin sensitivity. J Clin Endocrinol Metab 88:1785–1791

33.

Gan SK, Kriketos AD, Poynten AM et al (2003) Insulin action, regional fat, and myocite lipid: altered relationships with increased adiposity. Obes Res 11:1295–1305

Titel: Reduced whole-body lipid oxidation is associated with insulin resistance, but not with intramyocellular lipid content in offspring of type 2 diabetic patients
verfasst von: G. Lattuada
F. Costantino
A. Caumo
P. Scifo
F. Ragogna
F. De Cobelli
A. Del Maschio
L. Luzi
G. Perseghin
Publikationsdatum: 01.04.2005
Verlag: Springer-Verlag
Erschienen in: Diabetologia / Ausgabe 4/2005
Print ISSN: 0012-186X
Elektronische ISSN: 1432-0428
DOI: https://doi.org/10.1007/s00125-005-1686-6

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Reduced whole-body lipid oxidation is associated with insulin resistance, but not with intramyocellular lipid content in offspring of type 2 diabetic patients